These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 22552217)

  • 1. The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
    Bolla M
    Eur Urol; 2012 Aug; 62(2):220-1; author reply 222-3. PubMed ID: 22552217
    [No Abstract]   [Full Text] [Related]  

  • 2. Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: an open randomised phase 3 trial.
    Mottet N; Peneau M; Mazeron JJ; Molinie V; Richaud P
    Eur Urol; 2012 Aug; 62(2):213-9. PubMed ID: 22502942
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P; Castagnetti G; Ferrari G; Baisi B; Dotti A
    Urol Int; 1996; 56 Suppl 1():13-7. PubMed ID: 8776812
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Hepatic encephalopathy induced by flutamide administered for the treatment of prostatic cancer].
    Patel H; Rhee E; Zimmern PE
    J Urol (Paris); 1996; 102(3):123-5. PubMed ID: 9091557
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The opportunity cost of androgen suppression in locally advanced prostate cancer.
    Gray PJ; Efstathiou JA; Shipley WU
    Asian J Androl; 2013 May; 15(3):356-7. PubMed ID: 23435474
    [No Abstract]   [Full Text] [Related]  

  • 6. Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study.
    Sato N; Akakura K; Isaka S; Nakatsu H; Tanaka M; Ito H; Masai M;
    Urology; 2004 Aug; 64(2):341-5. PubMed ID: 15302491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemical andropause and amyloid-beta peptide.
    Gandy S; Almeida OP; Fonte J; Lim D; Waterrus A; Spry N; Flicker L; Martins RN
    JAMA; 2001 May; 285(17):2195-6. PubMed ID: 11325319
    [No Abstract]   [Full Text] [Related]  

  • 8. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA; Nicol DL; Green HJ; Yaxley J; Watson R; Mactaggart P; Headley BC; Swanson C; Pakenham KI
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract]   [Full Text] [Related]  

  • 9. Massive locally extensive prostate cancer.
    Rozanski TA; Faerber GJ
    Urology; 1994 Feb; 43(2):242-3. PubMed ID: 7509527
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adenocarcinoma of the prostate metastatic to the choroid of the eye.
    Keizur JJ; Kane CJ; North R; Leidich RB
    Prostate; 1995 Dec; 27(6):336-9. PubMed ID: 7501546
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapy with flutamide and castration (orchiectomy or LH-RH agonist) in untreated patients with advanced prostate cancer.
    Dupont A; Labrie F; Cusan L; Gomez JL; Tremblay M; Lacourcière Y; Emond J; Monfette G
    Recent Results Cancer Res; 1992; 124():43-54. PubMed ID: 1615218
    [No Abstract]   [Full Text] [Related]  

  • 12. Adenocarcinoma of the prostate with ectopic antidiuretic hormone production: a case report.
    Ito H; Nishimura T; Abe H; Oka F; Miura T; Uchikoba T; Oaki Y
    Hinyokika Kiyo; 2000 Jul; 46(7):499-503. PubMed ID: 10965460
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Harms versus benefits with duration of androgen suppression.
    Nguyen PL
    Lancet Oncol; 2012 Dec; 13(12):1182-3. PubMed ID: 23151430
    [No Abstract]   [Full Text] [Related]  

  • 14. Combination therapy with flutamide and castration (orchiectomy or LHRH agonist): the minimal endocrine therapy in both untreated and previously treated patients with advanced prostate cancer.
    Labrie F; Dupont A; Giguère M; Borsanyi JP; Lacourciere Y; Bélanger A; Lachance R; Emond J; Monfette G
    Prog Clin Biol Res; 1988; 260():41-62. PubMed ID: 3283766
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Hormone therapy of locally advanced cancer of the prostate validated by several randomized trials].
    Mazeron JJ
    Bull Cancer; 2011 Feb; 98(2):93-4. PubMed ID: 21591300
    [No Abstract]   [Full Text] [Related]  

  • 16. Androgen deprivation in men with prostate cancer is associated with an increased rate of bone loss.
    Preston DM; Torréns JI; Harding P; Howard RS; Duncan WE; McLeod DG
    Prostate Cancer Prostatic Dis; 2002; 5(4):304-10. PubMed ID: 12627216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [A posteriori biological demonstration of the concept of hormone-radiotherapy combination in cancer of the prostate].
    Magné N
    Bull Cancer; 2013 May; 100(5):415-6. PubMed ID: 23862197
    [No Abstract]   [Full Text] [Related]  

  • 18. [Evolution of endocrine therapy for prostate cancer].
    Igawa T; Saito Y
    Nihon Rinsho; 2000 Jul; 58 Suppl():176-81. PubMed ID: 11022709
    [No Abstract]   [Full Text] [Related]  

  • 19. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): secondary endpoints from a randomised phase 3 factorial trial.
    Denham JW; Wilcox C; Joseph D; Spry NA; Lamb DS; Tai KH; Matthews J; Atkinson C; Turner S; Christie D; Gogna NK; Kenny L; Duchesne G; Delahunt B; McElduff P
    Lancet Oncol; 2012 Dec; 13(12):1260-70. PubMed ID: 23151431
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Total androgen blockade].
    Namiki M; Mizokami A
    Nihon Rinsho; 2002 Dec; 60 Suppl 11():193-8. PubMed ID: 12599570
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.